［1］Yang Hui，Qiu Ling，Lin Jianguo，et al.Research progress on the treatment of zoledronic acid on breast cancer and the related skeletal metastases［J］.Modern Oncology，2016，24(8)：1306-1310.［杨慧，邱玲，林建国，等.唑来膦酸治疗乳腺癌及其骨转移的研究进展［J］.现代肿瘤医学，2016，24(8)：1306-1310.］
［2］Sarvari BK，Sankara Mahadev D，Rupa S，et al.Detection of Bone metastases in breast cancer (BC) patients by serum tartrate-resistant acid phosphatase 5b (TRACP 5b)，a bone resorption marker and serum alkaline phosphatase (ALP)，a bone formation marker，in lieu of whole body skeletal scintigraphy with technetium99m MDP［J］.Indian J Clin Biochem，2015，30(1)：66-71.
［3］Mori M，Mimori K，Inoue H，et al.Detection of cancer metastases in lymPh nodes by reverse transcriPtase-Polymerase chain reaction［J］.Cancer Res，2005，55(15)：3417-3420.
［4］Chiang PH，Wang HC，Lai YL，et al.Zoledronic acid treatment for cancerous bone metastases：a phase IV study in Taiwan［J］.Cancer Res Ther，2013，9(4)：653-659.
［5］Lee ming DJ，Koizumi M，Qvist P，et al.Serum N-terminal propeptide of collagen type I is associated with the number of bone metastases in breast and prostate cancer and correlates to other bone related markers［J］.Biomark Cancer，2011，9(3)：15-23.
［6］Ren L，Wang X，Dong Z，et al.Bone metastasis from breast cancer involves elevated IL-11 expression and the gp130/STAT3 pathway［J］.Med Oncol，2013，30(3)：634.
［7］Nowak Z，Konieczna M，Wankowicz Z，et al.Tartrate-resistant acid phosphatase-TRAP5b as a novel marker of bone resorption in patients with irreversible renal failure treated with dialysis［J］.Pol Merkuriusz Lek，2004，17(98)：138-141.
［8］Yu Yang，Zhou Liping.Research progress on molecular mechanisms of breast cancer bone metastasis［J］.Modern Oncology，2014，22(03)：693-696.［于洋，周立平.乳腺癌骨转移分子机制的研究进展［J］.现代肿瘤医学，2014，22(03)：693-696.］
［9］Wu J，Shao ZM，Shen KW，et al.Identifying factors related to bone metastasis in breast cancer［J］.China Oncology，2003，13(4)：316-325.［吴炅，邵志敏，沈坤炜，等.乳腺癌骨转移相关的临床病理因素的研究［J］.中国癌症杂志，2003，13(4)：316-325.］
［10］Gbel A，Thiele S，Browne AJ，et al.Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells［J］.Cancer Lett，2016，375(1)：162-171.
［11］Santini D，Stumbo L，Spoto C，et al.Bisphosphonates as anticancer agents in early breast cancer：preclinical and clinical evidence［J］.Breast Cancer Res，2015，17(4)：121.
［12］Chen LZ，Tang J，Wang YL，et al.Sermn TRACP5b detection and its significance in breast cancer with negative axillary lymph nodes［J］.Chin J Endocr Surg，2011，5(6)：377-379.［陈龙舟，唐静，王亚丽，等.淋巴结阴性乳腺癌血清Tracp5b检测及临床意义［J］.中华内分泌外科杂志，2011，5(6)：377-379.］
［13］Janckila AJ，Neustadt DH，Nakasato YR，et al.Serum tartrate-resistant acid PhosPhatase isoforms in rheumatoid arthritis［J］.Clin Chim Acta，2002，320(1-2)：49-58.
［14］Min HY，Li JJ，Zhang H，et al.The clinical value of serum VEGF and TRACP-5b as markers to diagnose bone metastases in lung carcinoma patients［J］.China Oncology，2011，21(3)：197-200.［闵海燕，李娟娟，张航，等.血清VEGF、TRACP-5b含量分析对肺癌骨转移患者的检测意义［J］.中国癌症杂志，2011，21(3)：197-200.］
［15］Reichel H，Esser A，Roth HJ，et al.Influence of PTH assay methodology on differential diagnosis of renal bone disease［J］.NePhrol Dial TransPlant，2003，18(4)：759-768.